Mechanism of Yeast Infections with Jardiance
Jardiance (empagliflozin) causes yeast infections by increasing glucose concentration in the urine and genital area, creating an ideal environment for Candida species to grow and proliferate. This occurs through the drug's primary mechanism of action: inhibiting SGLT2 glucose reabsorption in the kidneys, which leads to glucosuria (glucose in urine) 1.
How the Mechanism Works
The SGLT2 inhibition pathway directly creates conditions favorable for fungal overgrowth:
- Empagliflozin blocks sodium-glucose cotransporter-2 proteins in the proximal renal tubules, preventing glucose reabsorption
- This results in significant urinary glucose excretion (glucosuria), even when blood glucose is well-controlled 2, 3
- The elevated glucose in urine and on genital tissues provides an abundant nutrient source for Candida organisms
- The warm, moist genital environment combined with glucose creates optimal conditions for yeast proliferation 1
Clinical Manifestations and Risk Patterns
Genital mycotic infections occur more frequently in females than males 1. The FDA label data shows:
- Female genital infections: 5.4-6.4% with empagliflozin versus 1.5% with placebo
- Male genital infections: 3.1-1.6% with empagliflozin versus 0.4% with placebo 1
In females, infections present as vulvovaginal candidiasis with vaginal itching, white or yellowish discharge (often cottage cheese-like), and vaginal odor 1. In males, balanitis or balanoposthitis develops with penile redness, itching, swelling, rash, foul-smelling discharge, and pain around the penis 1.
A critical clinical point: These infections can occur even when diabetes is well-controlled. Recent case series demonstrate recurrent candidal balanoposthitis in patients with HbA1c levels between 5.0-5.6% after SGLT2 inhibitor initiation—well within normal range 2. This underscores that the mechanism is drug-induced glucosuria, not systemic hyperglycemia.
Sex-Specific Risk Factors
Recent evidence identifies distinct risk factors by sex 4:
- In females: Older age (≥65 years) combined with three or more concomitant antidiabetic medications significantly increases risk
- In males: Elevated body mass index is the primary risk factor
- The combination of older age and polypharmacy in females showed excellent discrimination for infection risk (concordance index 0.83) 4
Important Clinical Considerations
Most genital infections are mild to moderate in severity and respond to standard antifungal therapy 3, 5. The FDA label recommends over-the-counter topical antifungal agents as first-line treatment 1. However, patients should seek medical attention if symptoms persist after OTC treatment or recur within 2 months.
Phimosis can develop in uncircumcised males, with swelling making it difficult to retract foreskin 1. This occurred in 0.1% of empagliflozin 25mg users versus 0% with placebo 1.
The infection risk appears consistent across the SGLT2 inhibitor class, though recent comparative data suggests empagliflozin may have slightly higher relative risks of genital infections (RR 1.14) and phimosis (RR 1.23) compared to dapagliflozin, despite small absolute risk differences 6.
Discontinuation rates due to genital infections remain low (0.2% for empagliflozin) 1, and the infections do not appear to increase with longer treatment duration when examined over 5-year follow-up 6, 7.